A new drug is showing promising results in halting tumour growth.
The drug, currently named GDC-0941, has been tested on mice and was found to reduce growth of the brain tumour glioblastoma by up to 98 per cent.
Professor Paul Workman of the Institute of Cancer Research, London, UK, and colleagues explain that the drug targets the "PI3 kinase pathway", known to be involved in the growth and spread of many cancers.
It works by correcting faulty genetic signals that cause unrestricted cancer spread, and by preventing the action of cells that support the tumour’s blood supply.
In tests, it curbed the growth of glioblastoma and reduced the growth of ovarian tumours in mice by 80 per cent. It also appears to be effective against cells from other types of human cancers. Full details of the research appear in the journal Molecular Cancer Therapeutics.
Professor Workman said: "We know the PI3 kinase super-highway is hijacked in many cancers. We show here that GDC-0941 works in the way it was designed to, inhibiting the PI3 kinase pathway and blocking tumour growth.
"Our hope is that that we have created a potent anti-cancer weapon that directly targets the processes which feed the cancer cells while sparing most of the healthy cells. But it is early days and we still have a lot to learn about the potential of this drug. The next step is to see if the drug targets human cancers as effectively."
GDC-0941 is manufactured by the pharmaceutical company Genentech. The firm are now carrying out Phase I clinical trials of the drug using patients in the UK and the US.
Raynaud, F. I. et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Molecular Cancer Therapeutics, published online July 7, 2009.

Leave a Reply